| Project/Area Number |
17590975
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
TANAKA Junji Hokkaido University, Graduate School of Medicine, Associate Professor, 大学院医学研究科, 助教授 (50250452)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2006: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2005: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | Cell therapy / NK cell / GVHD / GVL / Stem cell transplantation / Leukemia |
|---|
| Research Abstract |
In this study, we could expand inhibitory NK cell receptor (CD94/NKG2A)-expressing CD8 T cells from G-CSF-mobilized peripheral blood mononuclear cells (G-PBMC), patients' derived autologous G-CSF-mobilized peripheral blood mononuclear cells (Auto G-PBMC) and cord blood by the stimulation of IL-15 and OKT3.
These expanded CD94 /NKG2A-expres sing CD8 T cells could attack HLA class I-low leukemic cell line such as K562 and patients' derived primary leukemic cells.
Also, it was reveled that activating NK cell receptor NKG2D and it's legand MICA/B were involved in the killing activity of CD94/NKG2A-expressing CD8 T cells.
|
